Skip to main content
. 2017 Aug 1;6(8):1952–1964. doi: 10.1002/cam4.1131

Figure 5.

Figure 5

Heatmap and concentration response curves for the addition of the Chk1 inhibitor, rabusertib, or the GSK3β inhibitor, LY‐2090314, to etoposide/carboplatin in the SCLC lines. A. Heatmap with the 63 SCLC lines listed from least responsive to most responsive to etoposide. Blue indicates greater than additive response to the combination of rabusertib with etoposide/carboplatin (I t = −0.181 ± 0.175). Yellow indicates additivity of rabusertib with etoposide/carboplatin. Red indicates less than additive response to the combination of rabusertib with etoposide/carboplatin. (B) Concentration response curves for representative SCLC lines exposed to rabusertib alone (dotted lines), or to the combination of rabusertib with etoposide (0.3 μmol/L) and carboplatin (3.7 μmol/L) (solid lines) that produced greater than additive cell killing. (C) Concentration response curves for representative SCLC lines exposed to rabusertib alone (dotted lines), or to the combination of rabusertib with etoposide (0.3 μmol/L) and carboplatin (3.7 μmol/L) (solid lines) that produced primarily additive cell killing. The color of the lines (dotted and solid) indicate the same SCLC line. (D) Heatmap with the 63 SCLC lines listed from least responsive to most responsive to etoposide. Blue indicates greater than additive response to the combination of LY‐2090314 with etoposide/carboplatin (I t = −0.105 ± 0.273). Yellow indicates additivity of LY‐2090314 with etoposide/carboplatin. Red indicates less than additive response to the combination of LY‐2090314 with etoposide/carboplatin. (E) Concentration response curves for representative SCLC lines exposed to LY‐2090314 alone (dotted lines), or to the combination of LY‐2090314 with etoposide (0.3 μmol/L) and carboplatin (3.7 μmol/L) (solid lines) that produced greater than additive cell killing. (F) Concentration response curves for representative SCLC lines exposed to LY‐2090314 alone (dotted lines), or to the combination of LY‐2090314 with etoposide (0.3 μmol/L) and carboplatin (3.7 μmol/L) (solid lines) that produced primarily additive cell killing. The color of the lines (dotted and solid) indicate the same SCLC line.